Relay Therapeutics (RLAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more ...

Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026Breast cancer triplet data ...

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 10:30 AM EDTCompany ParticipantsSanjiv Patel - ...

This clinical-stage biotech focused on precision oncology therapies reported an insider sale amid a year of sharp share price gains.

CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (RLAY) (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing ...

Relay Therapeutics shares were 16% higher, at $10.63, after the company reported fourth-quarter revenue that was higher than last year, and a narrower quarterly loss. The stock hit its 52-week high of ...

CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining ...

Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the top strong buy stocks under $5 to buy now. Leerink Partners analyst Andrew Berens reiterated a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) ...

Relay Therapeutics (NASDAQ:RLAY) is set to give its latest quarterly earnings report on Thursday, 2026-02-26. Here's what investors need to know before the announcement. Analysts estimate that Relay ...

Appointment of Claire Mazumdar, Ph.D., to the Board of Directors brings valuable strategic and operational experience in clinical-stage oncology, which may enhance the company's leadership as it ...